Status:
COMPLETED
Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Infections
Eligibility:
All Genders
65+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to provide data documenting the efficacy of daptomycin in elderly patients aged ≥ 65 years with complicated Skin and Soft Tissue Infections.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients 65 years or older with infection of sufficient severity to require in-patient hospitalization, with parenteral antimicrobial therapy for at least 96 hours.
- Patients who have a diagnosis of Gram-positive complicated Skin and Soft Tissue Infections (cSSTIs) with or without bacteremia:
- Wound infections,
- Major abscesses with or without recognized preceding trauma, that require antibiotic therapy in addition to surgical incision and drainage,
- Severe carbunculosis,
- Infected ulcers (except patients with multiple infected ulcers) associated with: diabetes, vascular insufficiency, pressure (i.e., decubitus ulcers).
- Exclusion criteria:
- Conditions requiring surgery that in and of itself would cure the infection or remove the infected site (e.g., amputation).
- Minor or superficial skin infections (e.g., furuncles, simple abscesses, acne, impetigo).
- Cellulitis, including erysipelas, not associated with complicating factors. However, patients with cellulitis associated with more serious infection (e.g., surgical wound, diabetic ulcer, deep tissue) can be enrolled (proportion of these patients will be limited to 30%).
- Infections for which outcome is difficult to assess:
- Perirectal abscess,
- Hidradenitis suppurativa,
- Gangrene,
- Infected human or animal bites,
- Multiple infected ulcers at distant sites,
- Infected burns (only third degree burn wound or wound area of more than 10 cm diameter),
- Conditions requiring emergency surgery including necrotizing fasciitis.
- Medical conditions:
- History of significant allergy or intolerance to Vancomycin or Daptomycin. Hypersensitivity to SSPs penicillins is not an exclusion criterion,
- Concomitant clinically suspected or confirmed other site of infection or disorder at study entry that may interfere with the evaluation in this protocol,
- Infections associated with a permanent prosthetic device that will not be removed within 24 hours after enrolment,
- Known or suspected HIV infection with a CD4+ T-cell count \< 500/μL (HIV testing is not required),
- Severe hepatic disease (Child-Pugh Class C) or ALT and/or AST \> 5 times ULN and/ or total bilirubin \> 2 times ULN at screening,
- Calculated creatinine clearance by the Cockcroft-Gault equation using actual body weight \< 30 mL/min or any type of dialysis,
- Treatment with any investigational agent or device within 30 days of study drug administration.
- Exclusion criteria related to medications:
- Previous systemic antibacterial therapy for the treatment of Gram-positive complicated skin and soft tissue infections for more than 24 hours within 48 hours prior to the day of first infusion of study drug unless:
- The previous antibacterial therapy was administered for 3 or more calendar days with either worsening or no improvement in the clinical signs and symptoms of cSSTIs, and was not Vancomycin or SSPs.
- Other protocol-defined inclusion/exclusion criteria applied.
Exclusion
Key Trial Info
Start Date :
March 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01184872
Start Date
March 1 2010
End Date
March 1 2011
Last Update
July 13 2012
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Graz, Austria
2
Novartis Investigative Site
Vienna, Austria
3
Novartis Investigative Site
Bochum, Germany
4
Novartis Investigative Site
Essen, Germany